Semaglutide non-injection: what the oral form means for weight loss

What the OASIS 4 trial actually found about non-injection semaglutide

The MHRA's June 2026 approval rested largely on the OASIS 4 phase 3 trial: 307 adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes, followed over 64 weeks. The headline figure is around 13.6% average body-weight reduction on the 25 mg tablet versus roughly 2.4% on placebo, both groups alongside lifestyle changes. That gap is clinically meaningful. Among the subset who stayed fully adherent to treatment, average loss reached approximately 17%, which is why some coverage leads with that number. Worth being precise: 17% is the adherent-participant figure, not the trial average. The most common side effects were gastrointestinal (nausea, diarrhoea, vomiting) reported in around 74% of the semaglutide group versus 42% on placebo. Broadly similar to the injection's profile, though individual experience varies. The MHRA's approval announcement, published on GOV.UK on 11 June 2026, confirms the licensed population: adults with a BMI of 30 or above, or 27–29.9 with at least one weight-related condition, used alongside a reduced-calorie diet and increased physical activity.

How the tablet differs from the injection in daily practice

The single biggest practical difference is storage. The Wegovy injection pen needs refrigerating at 2–8°C; the tablet sits at room temperature, and if you want the full details on keeping your medication in the best condition, our page on how to store semaglutide injection covers everything you need to know. That matters if you travel frequently or find cold-chain storage inconvenient. Injection users tend to pick a consistent day of the week and rotate sites, abdomen, thigh, upper arm. Tablet users instead build a morning habit: tablet first, then wait at least 30 minutes before coffee, food or any other oral medicines. Swallow it whole with no more than a small sip of plain water. That ritual matters because semaglutide's oral absorption is fragile; food and drink reduce it substantially. One practical check you can do in under a minute: before your first tablet each morning, look at the clock and set a 30-minute reminder on your phone so the waiting window doesn't slip. It sounds simple, but consistent adherence is exactly where the trial's best results were seen. If you are already established on the 2.4 mg weekly injection, the prescriber may consider moving you directly to the 25 mg tablet rather than restarting the titration from scratch, subject to clinical assessment, and if you need a refresher on the technique before switching, our guide on how to inject semaglutide walks through the full process clearly. For anyone still weighing up which form suits them, our guide to semaglutide injections covers the injection route in detail.

Eligibility and what 'prescription only' means here

Oral semaglutide for weight management is a prescription-only medicine. A prescriber assesses whether it is clinically appropriate, BMI thresholds are a starting point, not the whole picture. The licensed criteria broadly mirror the injection: BMI 30 or above, or 27–29.9 alongside a qualifying weight-related condition such as high blood pressure, raised cholesterol or obstructive sleep apnoea. Lower BMI thresholds may apply for some ethnic backgrounds under UK guidance. The Wegovy tablet is not currently available on the NHS; a NICE appraisal would be required before that pathway opens, so for now it is a private prescription only. That also means no waiting list. If you want to explore the broader range of weight-loss treatment options (including the injection) it helps to see them laid out side by side before deciding. One point to be clear on: Rybelsus is also oral semaglutide, but it is licensed for type 2 diabetes at 3 mg, 7 mg and 14 mg strengths. Those strengths are not part of the Wegovy weight-loss tablet schedule and should not be confused with it. The weight-loss tablet ladder is 1.5 mg, 4 mg, 9 mg and 25 mg. If you come across anything described differently, that is worth querying with a prescriber. For context on how UK pricing and what's included in a private prescription typically compare, our Wegovy price comparison page sets out what to look for.

Safety considerations that stay the same regardless of the format

Switching from needle to tablet does not change semaglutide's underlying pharmacology or its safety profile. The gastrointestinal effects that are common with the injection (nausea, constipation, reflux) appear with similar frequency in tablet users, particularly early in treatment or after a dose step up. They generally ease as the body adjusts. Pancreatitis is a known but infrequent risk with GLP-1 medicines; if you develop severe abdominal pain that spreads to the back, with or without vomiting, seek urgent medical attention. The MHRA's Yellow Card scheme allows patients to report any suspected side effect directly to the regulator, which is worth knowing regardless of which format you take. Semaglutide in any form is not recommended during pregnancy, while breastfeeding, or when actively trying to conceive. It is not licensed for under-18s. People with a history of certain thyroid conditions, pancreatitis or specific gastrointestinal disorders should discuss this with a prescriber before starting. If you use the injection alongside the tablet or are transitioning between the two, our page on semaglutide injection explains the full picture of what that route involves if it remains relevant to you. The NHS semaglutide medicines page is a reliable reference for side effects and contraindications across both formats. Our clinical team, led by our clinical director, reviews every consultation personally before any prescription is issued. Speak to our prescribers to find out whether the tablet or the injection suits your situation better, and if you opt for the pen, our page on whether you have to prime Wegovy every time answers one of the most common practical questions new users ask.